|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary Table 1. Post-treatment Cohort Characteristics.** | | | |
| **Response** | **Stage** | **Receptor Subtype** | **Neoadjuvant Treatment** |
| **pCR** | III | HER2+ | anthracycline + taxane |
| **pCR** | III | HER2+ | chemotherapy + anti-HER2 regimen |
| **pCR** | III | HR+/HER2- | chemotherapy + anti-EGFR regimen |
| **pCR** | III | HER2+ | chemotherapy + anti-HER2 regimen |
| **pCR** | III | HER2+ | chemotherapy + anti-HER2 regimen |
| **pCR** | IV | HER2+ | chemotherapy + anti-HER2 regimen |
| **Non-pCR** | III | TNBC | chemotherapy + anti-EGFR regimen |
| **Non-pCR** | III | TNBC | chemotherapy + anti-EGFR regimen |
| **Non-pCR** | III | TNBC | chemotherapy + anti-EGFR regimen |
| **Non-pCR** | III | HER2+ | chemotherapy + anti-HER2 regimen |
| **Non-pCR** | III | HR+/HER2- | anthracycline + taxane |
| **Non-pCR** | III | HR+/HER2- | anthracycline + taxane |
| **Non-pCR** | III | HR+/HER2- | chemotherapy + anti-EGFR regimen |
| **Non-pCR** | III | HR+/HER2- | chemotherapy + anti-EGFR regimen |
| **Non-pCR** | III | HR+/HER2- | chemotherapy + anti-EGFR regimen |
| **Non-pCR** | III | HR+/HER2- | chemotherapy + anti-EGFR regimen |
| **Non-pCR** | III | HR+/HER2- | chemotherapy + anti-EGFR regimen |
| **Non-pCR** | III | HER2+ | chemotherapy + anti-HER2 regimen |
| **Non-pCR** | III | HER2+ | chemotherapy + anti-HER2 regimen |
| **Non-pCR** | IV | TNBC | anthracycline + taxane |
| **Non-pCR** | IV | TNBC | anthracycline + taxane |
| **Non-pCR** | IV | TNBC | anthracycline + taxane |
| **Non-pCR** | IV | HER2+ | chemotherapy + anti-HER2 regimen |
| **Non-pCR** | IV | HR+/HER2- | anthracycline + taxane |
| **Non-pCR** | IV | HR+/HER2- | anthracycline + taxane |
| **Non-pCR** | IV | HR+/HER2- | anthracycline + taxane |
| **Non-pCR** | IV | HER2+ | chemotherapy + anti-HER2 regimen |
| pCR, pathologic complete response; HER2+, HER2/neu amplified; HR+/HER2-, hormone receptor (estrogen or progesterone receptor) positive, HER2/neu non-amplified; TNBC, triple negative breast cancer; EGFR, epidermal growth factor receptor | | | |